

Cumulative Index 2005

Note: Page numbers of article titles are in **boldface** type.

A

- Accelerated diagnostic protocols (ADPs), in CPUs, 504
- Accident(s), diving, patent foramen ovale and, history of, 98
- ACCORD trial, in prevention of cardiovascular outcomes in type 2 diabetes, 215
- ACE inhibitors. *See Angiotensin-converting enzyme (ACE) inhibitors.*
- ACI. *See Acute coronary ischemia (ACI).*
- ACI predictive instrument. *See Acute coronary ischemia (ACI) predictive instrument.*
- Acid(s), fatty, free, unbound, as biomarker of cardiac ischemia, 496
- ACI-TIPI, for real-time and retrospective decision support, 602–603
- ACI-TIPI clinical trial, multicenter, 603
- ACI-TIPI demonstration project, TIPI information system cardiac error reduction system based on, 608–611
- ACI-TIPI management tool, in medical error prevention, 605–606
- ACSs. *See Acute coronary syndromes (ACSs).*
- Acute care facilities, financial pressures on, 589–590
- Acute coronary ischemia (ACI), ED patients with, failure to hospitalize, studies of, 603–605
- Acute coronary ischemia (ACI) predictive instrument, original, 602
- Acute coronary syndromes (ACSs), **401–409**
clinical presentation of, chest discomfort in, 425–426
ED demands of, 590
ED triage for, medical error prevention in, **601–614**
- ACI-TIPI for real-time and retrospective decision support in, 602–603
decision support and risk reduction tolls for real-time use in, 602
ECG in, 603
multicenter clinical trial, 603
original ACI predictive instrument in, 602
future directions in, 589
in ED and CPUs, troponin for, 455–456
missed diagnoses of, in ED, **423–451**
angina pain equivalents and, 426–427
atypical presentation-related, 427–428
biochemical markers and, 435–437
biomarkers of neurohumoral activation and inflammation and, 437
cardiac imaging-related, 437–438
central aortic pressure-related, 438
chest discomfort-related, 425–426
clinical presentation-related factors, 425
computer-based decision aids and, 438–440
creatinine kinase and, 435–436
described, 423–424
ECG-related. *See also under Electrocardiography (ECG).*
ECG-related, 430–435
Goldman Chest Pain Protocol-related, 438–439
in women, causes of, 439–440
methodologic issues related to, 424–425
myocardial performance index-related, 438
myoglobin and, 436–437
outcomes of, 441–443
past medical history-related, 428–429
physical examination-related, 429–430
Q wave-related, 432
race-related, 440–441
technetium-99m sestamibi myocardial perfusion imaging-related, 438
troponin and, 436
prevalence of, 401, 601
risk scores, 403–404
risk stratification for, 402

Acute coronary (continued)

- suspected, evaluation of, imaging in, **517-530**
 - acute myocardial perfusion imaging, 517-518
 - cost-effectiveness of, 525
 - diagnostic value in, 518-522
 - in special populations, 524-525
 - incorporation into chest pain evaluation, 525-527
 - negative predictive value and prognosis, 519-521
 - radiopharmaceutical issues in, 522-523
 - sensitivity in, 518-519
 - tracer injection timing in, 523-524
 - troponin and, 523
 - treatment of, 404-407
 - antithrombotic agents in, 404-405
 - reperfusion therapy in, 407
 - STEMI-related, 406
 - thrombolysis in, 406-407
 - without myocardial infarction, evaluation of, imaging in, 519
- Acute myocardial infarction, diabetes mellitus and, management of, intensive glycemic control in, **111-128**
- Acute myocardial perfusion imaging, in suspected ACS evaluation, 517-518
- ADHF. *See Heart failure, acute decompensated.*
- ADPs. *See Accelerated diagnostic protocols (ADPs).*
- α -Adrenergic agonists, for diabetes and hypertension, 144
- ADVANCE trial, in prevention of cardiovascular outcomes in type 2 diabetes, 214-215
- Albumin, ischemia modified, as biomarker of cardiac ischemia, 496
- Albuminuria, cardiovascular disease in diabetics and, 132
- Aldosterone antagonists, in ADHF management in EDOU, 583
- Amplatzer atrial septal defect occluder, in patent foramen ovale closure, 78-79
- Amputation, for peripheral arterial disease in CKD, 231
- Amyloidosis, cardiac, NOD64 due to, 562
- Anemia
 - CKD and, 354
 - management of, in cardiovascular disease in renal transplant recipients, 338
- Aneurysmal patent foramen ovale, 40-41
- Angel Wings device, in patent foramen ovale closure, 79-80
- Angina, described, 559
- Angina pain, equivalents of, in ACS presentation, 428-429
- Angioplasty, for cardiovascular disease in CKD, 305-307
- Angiotensin, in diabetes mellitus prevention, 174
- Angiotensin II-receptor blockers, for diabetes and hypertension, 144-145
- Angiotensin-converting enzyme (ACE) inhibitors, for diabetes and hypertension, 142-143
- Ankle brachial index less than 0.90, peripheral arterial disease in CKD and, prevalence of, 226
- Anticoagulant(s), in ADHF management in EDOU, 583
- Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, 347
- Anti-inflammatory drugs, nonsteroidal in ADHF management in EDOU, 583
- in hypertension, 240-241
- Antioxidant(s)
 - in dialysis, studies of, 325-326
 - in uremia, 324-325
- Antiplatelet agents
 - for cardiovascular disease in renal transplant recipients, 337
 - for peripheral arterial disease in CKD, 230
- Antithrombotic agents, for ACSs, 404-405
- Arterial disease, CKD and, 277
- Arteriosclerotic cardiovascular disease, uremia-related factors for, 354
- Arteriovenous fistulae
 - for vascular access in hemodialysis, 249-250
 - failure of, pathology of, 257-258
 - prevalence of, 254-255
 - rationale for, 256
 - surveillance of, 256-257
 - venous stenosis in, pathogenesis of, 260-262
- Artery(ies), central, renal failure effects on, 313
- Atherogenesis, accelerated, renal failure and, 313

- Atherosclerosis, oxidative stress and, 320–321
- Atherothrombosis, inflammation and, biomarkers of, 491–492
- Atrial septal defect closure, in pediatric patients, 42–43
- Atrial septal defect occlusion system, in patent foramen ovale closure, 81–82
- Atrial septum, anatomy of, 36–37

B

- Balanced Budget Act (BBA), 589
- Balloon occlusion, temporary, trial of, 37–39
- BARI 2D study, in prevention of cardiovascular outcomes in type 2 diabetes, 216
- BBA. See *Balanced Budget Act (BBA)*.
- Beta-blockers
- for ADHF in EDOU, 583
 - for cardiovascular disease in renal transplant recipients, 337
 - for CHF in CKD, 279
 - for diabetes and hypertension, 144
- Biguanide(s), in prevention of cardiovascular disease in diabetics, 127–128
- Binding proteins, fatty acid, in ED and CPUs, 455
- Biochemical markers, missed diagnosis of ACS in ED due to, 437–439
- Biomarkers
- in ED and CPUs, 453–465
 - background of, 453–455
 - creatinine kinase myocardial band, 455
 - fatty acid binding protein, 455
 - for patients with ST elevation and myocardial infarction, 456–457
 - ischemia-related, 455–456
 - myoglobin, 455
 - troponin, 453–455
 - for high-risk patients with ACSs, 457–458
 - for intermediate and low risk patients, 458–460
 - for patients with ST elevation and myocardial infarction, 456–457
 - for renal failure patients, 460–461
 - of atherothrombosis and inflammation, 491–492
 - of CAD, 491–501
 - of cardiac ischemia, 495–497

- B-type (brain) natriuretic peptide, 496–497
 - ischemia modified albumin, 496
 - unbound free fatty acid, 496
 - of inflammation
 - CD40 ligand, 494–495
 - C-reactive protein, 492–494
 - IL-6, 494
 - IL-10, 495
 - lipoprotein-associated phospholipase A2, 494
 - selectins, 495
 - serum amyloid A, 495
 - of neurohumoral activation and inflammation, missed diagnoses of ACS in ED due to, 439
 - of plaque instability or rupture, 497–498
- Blood pressure
- management of
 - for peripheral arterial disease in CKD, 229
 - in cardiovascular disease in renal transplant recipients, 336
 - in prevention of cardiovascular outcomes in type 2 diabetes, 218–219
 - renal replacement therapy effects on, 386–387
 - target, in diabetics with hypertension, 148
 - thiazolidinediones effects on, in prevention of cardiovascular disease in diabetics, 129–130
- Body weight, cardiovascular disease in diabetics and, 132
- B-type (brain) natriuretic peptide
- as biomarker of cardiac ischemia, 496–497
 - vs. filling pressures, in ADHF management in EDOU, 575
- B-type (brain) natriuretic peptide assays, in ADHF management in EDOU, 574–575
- B-type (brain) natriuretic peptide confounders, in ADHF management in EDOU, 575
- Buttoned device, in patent foramen ovale closure, 79
- Bypass Angioplasty Revascularization Investigation 2 Diabetes Trial, 190–191

C

- CAD. See *Coronary artery disease (CAD)*.
- Calcification, vascular
- CKD and, 357
 - in renal failure, 373–384. See also *Renal failure, vascular calcification in*.

- Calcium channel blockers
for diabetes and hypertension, 144
in ADHF management in EDOU, 583
- Calcium-phosphate metabolism, renal replacement therapy effects on, 387-388
- Cardiac amyloidosis, NOCAD due to, 562
- Cardiac biomarker POCT
applications of, 474-476
in CPUs, **467-490**
algorithmic strategies, 479-481
cost-effectiveness of, 479-481
customer satisfaction, 481-482
multimarkers, 479-481
planning and implementation of, 482-484
risk management, 481-482
timeliness in, 478-479
TTAT in, 477-478
technologies for, 469-477
types of, 470-472
- Cardiac ischemia, biomarkers of, 495-497. See also *Biomarkers, of cardiac ischemia*.
- Cardiac valvular abnormalities, in CKD, 350
- Cardiologist(s), pediatric, in patent foramen ovale closure, **35-45**. See also *Patent foramen ovale, closure of, pediatric cardiologist in*.
- Cardiomyopathy
CKD and, 276
microvascular dysfunction and, NOCAD due to, 561
- CardioSEAL septal occluder, in patent foramen ovale closure, 74-77
- Cardiovascular diseases
arteriosclerotic, uremia-related factors for, 354
CKD and, **343-362, 363-372**. See also *Chronic kidney disease (CKD), cardiovascular disease due to*.
diabetes mellitus and
prevention of, **121-139**. See also *Diabetes mellitus, cardiovascular disease associated with, prevention of*.
type 2, prevention of. See also *Diabetes mellitus, type 2, cardiovascular outcomes in, prevention of*.
diabetes mellitus and, type 2, prevention of, **213-222**
ESRD and, 311, 349-350
mortality due to, 385
in renal replacement therapy patients, 349-350
in renal transplant recipients, management of, **331-342**. See also *Renal transplant recipients, cardiovascular disease in, management of*.
renal failure and, pathophysiology of, **311-317**. See also *Renal failure, cardiovascular disease and, pathophysiology of*.
- Cardiovascular events, renal replacement therapy and, 388-389
- Cardiovascular Health Study, 345-346, 353
- Cardiovascular risk factors, in diabetics, comprehensive risk reduction of, **195-212**. See also *Diabetes mellitus, cardiovascular risk factors in patients with, comprehensive risk reduction of*.
- Catheter(s)
cuffed double-lumen silicone, for vascular access in hemodialysis, 251-252
in patent foramen ovale closure, 41-42
- CD40 ligand, as biomarker of inflammation, 494-495
- Centers for Medicare and Medicaid Services (CMS), 591-593
- Central aortic pressure, missed diagnoses of ACS in ED due to, 440
- Central arteries, renal failure effects on, 313
- Chest discomfort, in ACS presentation, 427-428
- Chest pain
evaluation of, imaging of suspected ACS in, 525-527
in ED
EBCT for triaging patients with, **541-548**
MSCT for triaging patients with, 545
stimulant use-related, in CPUs, 554-555
with normal coronary angiogram, management of, **559-568**. See *Chest pain with normal coronary angiogram (NOCAD)*.
Chest pain centers (CPCs). See *Chest pain units (CPUs)*.
- Chest pain units (CPUs)
ADPs in, 504
biomarkers in, **453-465**. See also *Biomarkers, in ED and CPUs*.
concept of, **411-421**
cost effectiveness of, 418-419, **589-599**
described, 504
echocardiography in, **531-539**

- efficacy of, 415-418
 emergence of, 591
 examples of, 414-415
 exercise testing in, **503-516**
 as indicator of low clinical risk, 503-504
 described, 507-510
 early
 current guidelines for, 505-506
 initial recommendations for, 504-505
 initial studies of, 506-507
 immediate, 510-513
 in special groups, 512
 issues related to, 512-513
 vs. myocardial scintigraphy, 511-512
 federal regulations for, 593-594, 595-596
 for acute coronary syndrome patients, 591
 for special patients, **549-557**
 CAD-related, 551-553
 chest pain related to stimulant use, 554-555
 diabetics, 553-554
 women, 549-551
 implementation of, 411-414
 origin of, 589
 quality implications of, 594
 reimbursement issues related to, 591-593
 synonyms for, 504
 trans-theoretic Y model application in, 594, 596-598
 women in, management of, 549-551
- Chest pain with normal coronary angiogram (NOCAD)**
 cardiomyopathy and, 561
 coronary spasm and, 561, 563-564
 differential diagnosis of, 560
 endothelial dysfunction and, 559-561, 563
 epicardial disease and, 560-561
 hypertension and, 561
 management of, **559-568**
 microvascular disease and, 561-562, 565
 microvascular dysfunction and, 560, 565
 idiopathic, 562
 microvascular endothelial dysfunction and, 561, 565
 myocardial bridging due to, 561, 564-565
 noncoronary causes of, 560, 562
 diagnosis of, systemic approach to, 562-563
 pathophysiology of, 559-560
 prognosis of, 563-565
 valvular disease and, 562
- CHF.** See *Congestive heart failure (CHF)*.
- Children, atrial septal defect closure in, 42-43**
- Choline, whole blood, as biomarker of plaque instability or rupture, 497**
- Chronic kidney disease (CKD)**
 anemia and, 354
 arterial disease due to, 277
CAD in, 285-298
 assessment of, 285-286
 outcomes of, 293-294
 risk factors for
 in dialysis patients, 286-287
 in nondialysis patients, 287-289
 cardiac valvular abnormalities in, 350
 cardiovascular disease due to, **343-362, 363-372**
 accelerated, pathophysiology of, 350-357
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, 347
 British population-based study, 346
 Cardiovascular Health Study, 345-346
 described, 345-347
 Framingham Offspring community study, 346
 Hoorn study, 345
 HOPE study, 346
 managed care group database analysis, 346-347
 management of
 medical therapy in, 307-308
 primary angioplasty in, 305-307
 rationale for, 304-305
 pathophysiology of, 276-277
 percutaneous coronary interventions for, **299-310**
 creatinine levels after, outcome-related, 300-301
 renal protection for, rationale for, 301
 risk factors for, 299-300
 Second National Health and Nutrition Examination Survey mortality study, 346
 studies of, 345-347
 conclusions from, 347-349
- CHF in, 275-284**
 epidemiology of, 277
 management of, 278-280
 beta-blockers in, 279
 diabetes management in, 279
 dialysis in, 279
 digoxin in, 279
 diuretics in, 279
 erythropoietin in, 279
 hypertension management in, 278-279

Chronic kidney disease (CKD) (continued)

- nephrology referral in, 279
 - renin-angiotensin system interruption in, 279
 - smoking cessation in, 279
 - statins in, 279
 - pathophysiology of, 276–277
 - risk factors for, 277–278
 - chronic microinflammation and, 355–357
 - coronary pathobiology in, 304
 - diabetes mellitus and, 351, 365
 - dyslipidemia in, 351–353, 364–365
 - interactions between, mechanisms for, 366
 - treatment of, 366–367
 - erythropoietin for, 354–355
 - health care perspective on, 275
 - hypertension in, **237–248**, 350. See also *Hypertension, in CKD*.
 - inflammation in, markers of, 353
 - ischemic heart disease due to, 276–277
 - left ventricular hypertrophy and, 355
 - lipids and, 365
 - microalbuminuria and, 350–351
 - myocardial stress in, biomarkers of, 357–358
 - nontraditional modifiable factors in, 353
 - oxidative pathways in, **319–330**. See also *Oxidative stress*.
 - oxidative stress and, 355–357
 - patient perspective on, 275–276
 - peripheral arterial disease in
 - ankle brachial index less than 0.90 due to, prevalence of, 226
 - diagnostic testing for, 226–227
 - epidemiology of, 225–228
 - impact of, 228
 - incidence of, 227–228
 - intermittent claudication due to, prevalence of, 225–226
 - management of, **225–236**
 - amputation in, 231
 - antiplatelet agents in, 230
 - blood pressure-lowering agents in, 229
 - cilostazol in, 230
 - exercise in, 230
 - revascularization in, 230–231
 - smoking cessation in, 229–230
 - statin therapy in, 228–229
 - surgical, 230–231
 - prevalence of, 225
 - peripheral vascular disease in
 - outcomes of, 290–293
 - risk factors for, 289–290
 - proteinuria and, 350–351
 - stages of, 343–344, 364
 - impact on cardiovascular biology, 344–345
 - valve replacement in, 350
 - vascular calcification and, 357
- Cilostazol, for peripheral arterial disease in CKD, 230
- CKD. See *Chronic kidney disease (CKD)*.
- Claudication, intermittent, peripheral arterial disease in CKD and, prevalence of, 225–226
- CMS. See *Centers for Medicare and Medicaid Services (CMS)*.
- Coagulation, cardiovascular disease in diabetics and, 131
- Cocaine, in hypertension, 240
- Computer-based decision aids, missed diagnoses of ACS in ED due to, 440–442
- Congenital heart disease, patent foramen ovale and, 37–39
- Congestive heart failure (CHF)
 - cardiovascular disease in renal transplant recipients due to, 333–334
 - in CKD, **275–284**. See also *Chronic kidney disease (CKD)*, *CHF in*.
- Consent, informed, for patent foramen ovale closure, 18–19
- Contrast-induced nephropathy
 - pathophysiology of, 301–302
 - prevention of, 302–304
- Coronary angiogram, normal, chest pain and, management of, **559–568**. See also *Chest pain with normal coronary angiogram (NOCAD)*.
- Coronary artery bypass grafting, percutaneous coronary intervention vs., in diabetics, **187–193**. See also *Diabetes mellitus*, *percutaneous coronary intervention vs. coronary artery bypass grafting in*.
- Coronary artery disease (CAD)
 - biomarkers of, **491–501**
 - in CKD, **285–298**. See also *Chronic kidney disease (CKD)*, *CAD in*.
 - likelihood of, 402–403
 - management of, in CPUs, 551–553
 - prevalence of, 402–403
- Coronary revascularization, in diabetics, 187
- Coronary spasm, NOCAD due to, 561, 563–564
- CPUs. See *Chest pain units (CPUs)*.

- C-reactive protein, as biomarker of inflammation, 492-494
- Creatine kinase, missed diagnoses of ACS in ED due to, 437-438
- Creatine kinase myocardial band, in ED and CPCs, 455
- Cuffed double-lumen silicone catheters, for vascular access in hemodialysis, 251-252
- Cyclosporine, in hypertension, 240

D

Diabetes mellitus

- acute myocardial infarction with, management
 - of, intensive glycemic control in, **111-128**
- as coronary heart disease risk-equivalent, 155
- burden of, 167
- cardiovascular disease associated with
 - albuminuria and, 132
 - body weight and, 132
 - coagulation and, 131
 - fibrinolysis and, 131
 - glycemic control effects on, 122-123
 - inflammation and, 131
 - insulin resistance effects on, 122-123
 - insulin sensitizing agents effects on, 123
 - prevalence of, 121
 - prevention of, **121-139**
 - insulin secretagogues in, 123-126
 - insulin sensitizing agents in, 127-132
 - metformin in, 128
 - nonsulfonylurea secretagogues in, 127
 - thiazolidinediones in, 128-131
 - treatment of, 132-133
- cardiovascular risk factors in patients with comprehensive reduction of, **195-212**
 - current state of affairs, 209-210
 - dyslipidemia, 197-199
 - future directions related to, 209-210
 - hyperglycemia, 202-203
 - hypertension, 199-202
 - increased thrombotic tendency, 203-204
 - multiple risk factor intervention for, 204-208
 - practical considerations related to, 208-209
- CKD and, 351, 365
- coronary revascularization in, 187
- ESRD due to, 363
- hypertension and, **141-153**
 - described, 141-142
 - renal failure with, treatment of, 147
 - target blood pressure in patients with, 148
 - treatment of
 - ACE inhibitors in, 142-143
 - α -adrenergic agonists in, 144
 - angiotensin II-receptor blockers in, 144-145
 - antihypertensive agents in, 145-147
 - β -blockers in, 144
 - calcium channel blockers in, 144
 - combination therapy in, 148-150
 - drugs in, 142-150
 - surrogate markers in, 147
 - thiazide diuretics in, 143-144
- lipid management in, **155-164**
 - combination therapy in, 161-162
 - evidence from, 156-157
 - goals in, 159
 - principles of, 159-161
- lipoprotein abnormalities associated with, 155-156
- management of
 - in CHF in CKD, 279
 - in CPUs, 553-554
 - renin-angiotensin system in, 168-170
- new onset, renin angiotensin system in, 176-177
- percutaneous coronary intervention *vs.* coronary artery bypass grafting in, **187-193**
 - Bypass Angioplasty Revascularization Investigation 2 Diabetes Trial, 190-191
 - described, 187-189
 - emerging therapies, 191-192
 - repeat vascularization, 189
- prevention of
 - lifestyle modifications in, 168, 174-176
 - renin angiotensin system in, **167-185**
- renin-angiotensin system in, **167-185**
 - activation of, 170-172
 - as preventive agent, **167-185**
 - as therapeutic agent, **167-185**
 - in endothelial function, 174
 - in new onset diabetes, 176-177
 - in vascular endothelial function, 172-173
 - interaction between angiotensin, endothelium, and insulin resistance, 174, 177-180
- risk factors for, 167-168
- triglyceride and high-density lipoprotein intervention in, 157-159
- type 2
 - cardiovascular outcomes in, prevention of, **213-222**
 - blood pressure interventions in, 218-219

Diabetes mellitus (*continued*)

- clinical trials examining glycemic management techniques in, 215-218
- clinical trials examining glycemic targets in, 214-215
- lifestyle interventions in, 219-220
- lipids in, 218-219
- nonglycemic therapies in, 218-220
- revascularization interventions in, 218 described, 213

Diagnostic value

- in suspected ACS evaluation, 518-522
- incremental, in suspected ACS evaluation, 521-522

Dialysis

- antioxidants in, studies of, 325-326
- hypertension in patients on, 241-242
- in CHF in CKD management, 279

Digoxin

- in ADHF management in EDOU, 583
- in CHF in CKD management, 279

Diuretic(s)

- in ADHF management in EDOU, 581-582
- in CHF in CKD management, 279
- thiazide, for diabetes and hypertension, 143-144

Diving, patent foramen ovale and, **97-104**. See also *Patent foramen ovale, diving and*.

Diving accidents, patent foramen ovale and, history of, 98

DREAM study, in prevention of cardiovascular outcomes in type 2 diabetes, 217-218

Drug(s), in hypertension, 240-241

Dyslipidemia

- in CKD, 351-353, 364-365
- mechanisms for, 366
- treatment of, 366-367
- in diabetes mellitus, 197-199

E

EBCT. See *Electron beam CT (EBCT)*.

ECG. See *Electrocardiography (ECG)*.

Echocardiographer(s), in placement of patent foramen ovale closure devices, **53-64**

Echocardiography

- in CHCs, **531-539**

intracardiac, in placement of patent foramen ovale closure devices, pertinent views to obtain with, 57-60

missed diagnoses of ACS in ED due to, 439-440

three-dimensional

- in patent foramen ovale diagnosis, 51
- in placement of patent foramen ovale closure devices, 60-64

transesophageal

- in patent foramen ovale diagnosis, 49-50
- in placement of patent foramen ovale closure devices, 54-57
- transthoracic, in patent foramen ovale diagnosis, 47-49

ED. See *Emergency department (ED)*.

EDOU. See *Emergency department (ED) observation unit (OU)*.

Education

- family, patent foramen ovale closure device-related, 18-19
- patient, patent foramen ovale closure device-related, 18-19

Electrocardiography (ECG)

- continuous/serial ECG, in ACS diagnosis, 437
- diagnostic accuracy of, in ACS diagnosis, 432-437
- exercise stress, in ACS diagnosis, 437
- "nondiagnostic" patterns of, in ACS diagnosis, 434
- non-standard lead, in ACS diagnosis, 437
- normal, in ACS diagnosis, 434
- prehospital 12-lead, in ACS diagnosis, 434-437
- with ACI-TIPI for real-time and retrospective decision support in medical error prevention in ED triage for ACS, 603

Electrolyzed-reduced water treatment, for hemodialysis, 326

Electron beam CT (EBCT), for triaging patients presenting to ED with chest pain, **541-548**

Emergency department (ED)

- acute coronary syndrome demands on, 588
- biomarkers in, **453-465**. See also *Biomarkers, in ED and CPUs*.
- chest pain in patients presenting to, EBCT for triaging, **541-548**
- missed diagnoses of ACSs in, **423-451**. See also *Acute coronary syndromes (ACSs), missed diagnoses of, in ED*.

- Emergency department (ED) observation unit (OU), in ADHF management, **569–588**. See also *Heart failure, acute decompensated*.
 aldosterone antagonists in, 583
 anticoagulants in, 583
 beta-blockers in, 583
 B-type natriuretic peptide assays in, 574–575
 B-type natriuretic peptide confounders in, 575
 B-type natriuretic peptide *vs.* filling pressures in, 575
 calcium channel blockers in, 583
 candidates for, 578–581
 diagnostic evaluation in, 572
 digoxin in, 583
 diuretics in, 581–582
 early management, benefits of, 578
 economics of, 569–570
 general support in, 577–578
 neurohormones in, 572–573
 NSAIDs in, 583
 N-terminal pro-B-type natriuretic peptide in, 576–577
 OU disposition in, 583–584
 vasodilators in, 582
- Emergency department (ED) triage, for ACS, medical error prevention in, **601–614**. See also *Acute coronary syndrome (ACS)*, *ED triage for, medical error prevention in*.
- Endothelial function, renin angiotensin system in, 174
- Endothelial sodding/seeding, for venous neointimal hyperplasia in dialysis access, 265–266
- Endothelium
 dysfunction of, NOCAD due to, 559–561, 563
 function of, 559–560
 in diabetes mellitus prevention, 174
- End-stage renal disease (ESRD); cardiovascular disease in, 349–350
 cardiovascular risk in, 311
 death due to, causes of, 385
 diabetes and, 363
- Epicardial disease, NOCAD due to, 560–561
- Erythropoietin
 for CKD, 354–355
 in CHF in CKD management, 279
 in hypertension, 240
- ESRD. See *End-stage renal disease (ESRD)*.
- Exercise, for peripheral arterial disease in CKD, 230
- Exercise testing, in CPUs, **503–516**. See also *Chest pain units (CPUs)*, *exercise testing in*.
-
- F**
- Family education, patent foramen ovale closure device-related, 18–19
- Fatty acid(s), free, unbound, as biomarker of cardiac ischemia, 496
- Fatty acid binding protein, in ED and CPCs, 455
- Fibrinolysis, cardiovascular disease in diabetics and, 131
- Fistula(ae), arteriovenous. See *Arteriovenous fistulae*.
- Free fatty acid(s), unbound, as biomarker of cardiac ischemia, 496
-
- G**
- Gene therapy, for venous neointimal hyperplasia in dialysis access, 265
- Glycemic control, intensive, for acute myocardial infarction in diabetics, **111–118**
- Glycemic management techniques, in prevention of cardiovascular outcomes in type 2 diabetes, clinical trials of, 215–218
- Glycemic targets, in prevention of cardiovascular outcomes in type 2 diabetes, clinical trials of, 214–215
- Goldman Chest Pain Protocol, missed diagnoses of ACS in ED due to, 440–441
-
- H**
- Headache(s), migraine, patent foramen ovale in, **91–96**. See also *Patent foramen ovale, in migraine headache*.
- Heart, renal failure effects on, 313–314
- Heart disease
 congenital, patent foramen ovale and, 37–39
 ischemic
 cardiovascular disease in renal transplant recipients due to, 334–335
 CKD and, 276–277
- Heart failure
 acute decompensated
 clinical features of, 573

Heart failure (continued)

- diagnostic evaluation of, 7-8, 574
- differential diagnosis of, 573-574
- management of, in EDOU, **569-588**. See also *Emergency department (ED) observation unit (OU)*, in *ADHF management*.
- pathophysiology of, 571-572
- prognosis of, 576
- epidemiology of, 569-571
- vascular access in hemodialysis and, 253-254

Heart Outcome and Prevention Evaluation (HOPE) study, subgroup analyses of, 346**Helix device, in patent foramen ovale closure, 81****Hemodialysis**

- electrolyzed-reduced water treatment for, 326
- home, nocturnal, cardiovascular improvements and, physiologic link between, 389
- hypertension in, reverse epidemiology of, 243-244
- vascular access in, **249-273**
 - arteriovenous fistulae, 249-250
 - pathology of, 257-258
 - prevalence of, 254-255
 - rationale for, 256
 - surveillance of, 256-257
 - venous stenosis in, pathogenesis of, 260-262
 - clinical standard of care for, 254-257
 - complications of, 252-254
 - cuffed double-lumen silicone catheters, 251-252
 - dysfunction of, management of, lack of effective therapies in, 262-264
 - future directions in, 266-267
 - heart failure due to, 253-254
 - infections due to, 252-253
 - polytetrafluoroethylene grafts, 250-251
 - venous stenosis in, pathogenesis of, 260-262
 - types of, 249-254
 - venous neointimal hyperplasia in, novel therapies for, 264-266

Hemodialyzer(s), vitamin E-bonded, 326**Home hemodialysis, nocturnal, cardiovascular improvements and, physiologic link between, 389****Homocysteine, levels of, renal replacement therapy effects on, 388****Hoorn study, 345****HOPE study, subgroup analyses of, 346****Hypercoagulable states, in patent foramen ovale, 65-71****Hyperglycemia, in diabetes mellitus, 202-203****Hyperparathyroidism, renal replacement therapy effects on, 387-388****Hypertension**

- diabetes mellitus and, **141-153**, 199-202. See also *Diabetes mellitus, hypertension and*.
- in CKD, **237-248**, 350
 - management of, 241, 278-279
 - agents in, 242-243
- in dialysis patients, 241-242
- in hemodialysis, reverse epidemiology of, 243-244
- microvascular dysfunction and, NOCAD due to, 559
- pathophysiology of, 237-241
 - circulating inhibitors of nitric oxide in, 239
 - cocaine in, 240
 - cyclosporine in, 240
 - drugs in, 240-241
 - erythropoietin in, 240
 - lead in, 240
 - nitric oxide in, 239
 - NSAIDs in, 240-241
 - oxidative stress in, 238-239
 - renin-angiotensin system in, 238
 - sodium and water in, 237-238
 - sympathetic nervous system in, 239-240
 - toxins in, 240

Hypoxemia, nocturnal, renal replacement therapy and, 388**I****IL. See *Interleukin(s) (IL)*.****Imaging, in suspected ACS evaluation, 517-530. See also specific modalities and *Acute coronary syndromes (ACSs)*, suspected, evaluation of, imaging in.****Incremental diagnostic value, in suspected ACS evaluation, 521-522****Infection(s), vascular access in hemodialysis and, 252-253****Infiltrative disease, microvascular dysfunction and, NOCAD due to, 562**

Inflammation

- atherothrombosis and, biomarkers of, 491-492
- biomarkers of, 491-495. See also *Biomarkers, of inflammation.*
- missed diagnoses of ACS in ED due to, 439
- cardiovascular disease in diabetics and, 131
- oxidative stress and, in CKD, 323-324

Informed consent, for patent foramen ovale closure, 18-19

Insulin resistance

- cardiovascular disease in diabetics and, 122-123
- in diabetes mellitus prevention, 174, 177-180

Insulin secretagogues, 123-126

- in prevention of cardiovascular disease in diabetics, **121-139**
- sulfonylureas, 123-126

Insulin sensitizing agents, 127-132

- in prevention of cardiovascular disease in diabetics, **121-139**
- biguanides, 127-128

Interleukin(s) (IL)

- IL-6, as biomarker of inflammation, 494
- IL-10, as biomarker of inflammation, 495

Intracardiac echocardiography, in placement of patent foramen ovale closure devices, pertinent views to obtain with, 57-60

Intracardiac shunt, closure of, effect on migraines, 94

Ischemia

- cardiac, biomarkers of, 455-456, **491-501**. See also *Biomarkers, of cardiac ischemia.*
- myocardial, in ED and CPU patients, troponin for, 456-457

Ischemia modified albumin, as biomarker of cardiac ischemia, 496

Ischemic heart disease

- cardiovascular disease in renal transplant recipients due to, 334-335
- CKD and, 276-277

K

Kidney disease. See *Renal disease.*

L

Lead, in hypertension, 240

Left ventricular hypertrophy

cardiovascular disease in renal transplant recipients due to, 332-333

CKD and, 355

Lifestyle modifications

- in diabetes prevention, 168, 174-176
- in prevention of cardiovascular outcomes in type 2 diabetes, 219-220

Ligand(s), CD40, as biomarker of inflammation, 494-495

Lipid(s)

- CKD due to, 365
- in diabetes, management of, **155-164**. See also *Diabetes mellitus, lipid management in.*
- in prevention of cardiovascular outcomes in type 2 diabetes, 218-219
- renal failure due to, 365-366
- renal replacement therapy effects on, 387

Lipoprotein(s)

- abnormalities associated with, diabetes-related, 155-156
- low-density, malondialdehyde-modified, as biomarker of plaque instability or rupture, 497-498

Lipoprotein-associated phospholipase A2, as biomarker of inflammation, 494

Low-density lipoprotein, malondialdehyde-modified, as biomarker of plaque instability or rupture, 497-498

M

Malondialdehyde-modified low-density lipoprotein, as biomarker of plaque instability or rupture, 497-498

Medical errors, in ED triage for ACS, prevention of, **601-614**. See also *Acute coronary syndrome (ACS), ED triage for, medical error prevention in.*

Metformin, in prevention of cardiovascular disease in diabetics, 128

Microalbuminuria, CKD and, 350-351

Microinflammation, chronic, CKD and, 355-357

Microvascular disease, NOCAD due to, 561-562

Microvascular dysfunction

- cardiomyopathy and, NOCAD due to, 561
- hypertension and, NOCAD due to, 561
- idiopathic, NOCAD due to, 562
- infiltrative disease and, NOCAD due to, 562

- Microvascular dysfunction (*continued*)
 NOCAD due to, 560–562, 565
 valvular disease and, NOCAD due to, 562
- Microvascular endothelial dysfunction, NOCAD due to, 561, 565
- Microvascular system, function of, 560
- Migraine(s)
 closure of intracardiac shunt effects on, 94
 patent foramen ovale in, **91–96**.
 See also *Patent foramen ovale*,
 in *migraine headache*.
- MSCT, for triaging patients presenting to ED with chest pain, 545
- Myeloperoxidase, oxidative stress and inflammation in uremic patients through, 323–324
- Myocardial bridging, NOCAD due to, 561, 564–565
- Myocardial infarction, ACS without, evaluation of, imaging in, 519
- Myocardial ischemia, in ED and CPU patients, troponin for, 456–457
- Myocardial performance index, missed diagnoses of ACS in ED due to, 440
- Myocardial perfusion imaging, acute, in suspected ACS evaluation, 517–518
- Myocardial scintigraphy, *vs.* exercise testing, in CPUs, 511–512
- Myocardial stress, in CKD, biomarkers of, 357–358
- Myoglobin
 in ED and CPUs, 455
 missed diagnoses of ACS in ED due to, 438–439

N

- NAVIGATOR trial, in prevention of cardiovascular outcomes in type 2 diabetes, 217
- Negative predictive value, in suspected ACS evaluation, 519–521
- Nephropathy, contrast-induced pathophysiology of, 301–302
 prevention of, 302–304
- Nesiritide, in ADHF management in EDOU, 582

- Neurohormone(s), in ADHF management in EDOU, 572–573
- Neurohumoral activation, biomarkers of, missed diagnoses of ACS in ED due to, 439
- Nitric oxide
 circulating inhibitors of, in hypertension, 239
 in hypertension, 239
- NOCAD. See *Chest pain with normal coronary angiogram (NOCAD)*.
- Nocturnal home hemodialysis, cardiovascular improvements and, physiologic link between, 389
- Nocturnal hypoxemia, renal replacement therapy and, 388
- Nonglycemic therapies, in prevention of cardiovascular outcomes in type 2 diabetes, 218–220
- Non-ST elevation ACS, treatment of
 acute, 405
 invasive *vs.* conservative, 405
- Nonsulfonylurea secretagogues, 127
- NSAIDs. See *Anti-inflammatory drugs, nonsteroidal*.
- N-terminal pro-B-type natriuretic peptide, in ADHF management in EDOU, 576–577

O

- ORIGIN trial, in prevention of cardiovascular outcomes in type 2 diabetes, 217
- Oxidative pathways, in CKD, **319–330**
- Oxidative stress
 described, 319–320
 in atherosclerosis, 320–321
 in CKD, 355–357
 prevalence of, 321–323
 in hypertension, 238–239
 inflammation and, in CKD, 323–324

P

- Pain, chest, in ED
 EBCT for triaging patients with, **541–548**
 MSCT for triaging patients with, 545
- Patent foramen ovale, **1–6**
 aneurysmal, 40–41
 closure devices for
 assessment of, randomized trials of, 16–17
 described, 13–14

- indications for, 17-18
- operator skills with, 19-20
- overview of, 14-15
- patient and family education related to, 18-19
- placement of
 - echocardiographer's role in, **53-64**
 - echocardiography in, general approach to, 53-54
 - intracardiac echocardiography in, pertinent views to obtain with, 57-60
 - three-dimensional echocardiography in, 60-64
 - transesophageal echocardiography in, 54-57
- published reports of, 15-16
- closure of, **73-83**
 - atrial septal anatomy effects on, 39-40
 - atrial septal defect-related, in pediatric patients, 42-43
 - cardiac catheterization laboratory set-up for, 21-22
 - catheter approach to, 41-42
 - closure devices for, **13-35**
 - complications of
 - management of, 30-32
 - prevention of, 30-32
 - recognition of, 30-32
- congenital heart disease and, 37-39
- decompression pathology related to, 99-100
- defined, 1-2
- diagnosis of, **47-52**
 - three-dimensional echocardiography in, 51
 - traditional methods in, 47
 - transesophageal echocardiography in, 49-51
 - transthoracic echocardiography in, 47-49
- diving and, **97-104**
 - accidents related to, history of, 98
 - changing patency over time, 100-102
 - increased risk with, 98-99
 - prospective evaluation of, 100
- effectiveness of, 43
- hand-off back to referring physician after, 29-30
- hematologic ramifications of, **65-71**. See also *Patent foramen ovale, hypercoagulable state in*.
 - medical therapy for, 69-70
- historical perspective of, 35-36, **73-83**
 - Amplatzer atrial septal defect occluder, 78-79
 - Angel Wings device, 79-80
 - atrial septal defect occlusion system, 81-82
 - buttoned device, 79
 - CardioSEAL septal occluder, 77
 - Helex device, 81
 - percutaneous devices, 74-77
 - STARFlex septal occluder, 78
 - transcatheter patch occlusion, 80-81
- hypercoagulable state in, **65-71**
 - arterial, 66-67
 - implications of, 67-68
 - testing for, 68-69
 - venous, 65-66
- in migraine headache, **91-96**
 - positive effect of, 93-94
 - prevalence of, 91-93
- in special patient populations, 32-33
- informed consent for, 18-19
- mechanisms for, 5
- out-patient follow-up issues, 29-30
- pathophysiology of, 2-5
- patient preparation for, 21
- pediatric cardiologist in, **35-45**
 - future role of, 44
- percutaneous devices in, historical perspective of, 74-77
- platypnea-orthodeoxia syndrome and, **85-89**. See also *Platypnea-orthodeoxia syndrome*.
 - postprocedure care, 28-29
 - procedure of, 22-28
 - risks associated with, 43-44
 - shunt detection in, traditional, 47
 - size of, 5
 - stroke and, **7-11**
 - prevalence of, 7-8
 - temporary balloon occlusion trial in, 37-39
- Patient education, patent foramen ovale closure device-related, 18-19
- Peptide(s), B-type (brain) natriuretic, as biomarker of cardiac ischemia, 494-495
- Percutaneous coronary intervention, coronary artery bypass grafting vs., in diabetics, **187-193**. See also *Diabetes mellitus, percutaneous coronary intervention vs. coronary artery bypass grafting in*.
- Percutaneous devices, in patent foramen ovale closure, historical perspective of, 74-77
- Percutaneous patent foramen ovale, closure of, **13-35**. See also *Patent foramen ovale, closure of*.

- Peripheral arterial disease, in CKD,
management of, **225-236**. See also *Chronic kidney disease (CKD)*, *peripheral arterial disease in, management of*.
- Peripheral vascular disease, in CKD, risk factors for, 289-290
- Perivascular drug delivery, local, for venous neointimal hyperplasia in dialysis access, 265
- Phospholipase A2, lipoprotein-associated, as biomarker of inflammation, 494
- Plaque instability or rupture, biomarkers of, 497-498
- Plasma protein-A, pregnancy-associated, as biomarker of plaque instability or rupture, 497
- Platypnea-orthodeoxia syndrome
clinical entities associated with, 85-86
diagnosis of, 87-88
noncardiac mechanisms of, 86-87
patent foramen ovale and, **85-89**
pulmonary perfusion abnormalities with, 87
underlying mechanisms of, 85-86
- POCT. See *Point-of-care testing (POCT)*.
- Point-of-care testing (POCT)
cardiac biomarker. See *Cardiac biomarker POCT*.
in CPUs, **467-490**. See also *Cardiac biomarker POCT, in CPUs*.
defined, 467-468
goals of, 467-468
trends in, 467-468
- Polytetrafluoroethylene grafts
failure of, pathology of, 258-260
for vascular access in hemodialysis, 250-251
venous stenosis in, pathogenesis of, 260-262
- Predictive value, negative, in suspected ACS evaluation, 519-521
- Pregnancy-associated plasma protein-A, as biomarker of plaque instability or rupture, 497
- PROactive trial, in prevention of cardiovascular outcomes in type 2 diabetes, 216
- Protein(s)
binding, fatty acid, in ED and CPUs, 455
C-reactive, as biomarker of inflammation, 492-494
fatty acid binding, in ED and CPUs, 455
- Protein-A, plasma, pregnancy-associated, as biomarker of plaque instability or rupture, 497
- Proteinuria, CKD and, 350-351
- Pulmonary perfusion abnormalities, platypnea-orthodeoxia syndrome and, 87
-
- ## Q
- Q waves, in ACS diagnosis, 434
-
- ## R
- Race, as factor in missed diagnoses of ACS in ED, 442-443
- Radiation therapy, for venous neointimal hyperplasia in dialysis access, 264-265
- Radiopharmaceutical issues, in suspected ACS evaluation, 522-523
- RECORD study, in prevention of cardiovascular outcomes in type 2 diabetes, 216
- Reimbursement issues, CPU-related, 591-593
- Renal disease
chronic, hypertension in, **237-248**. See also *Hypertension, in CKD*.
high-risk, percutaneous coronary interventions for, **299-310**
incipient, cardiovascular risk in, 311-312
risk factor profile, 312-313
- Renal failure
cardiovascular disease and, pathophysiology of, **311-317**
accelerated atherogenesis in, 313
central arteries in, 313
heart in, 313-314
risk factor profile in, 312-313
in diabetics with hypertension, treatment of, 147
in ED and CPUs, troponin for, 460-461
lipids and, 365-366
vascular calcification in, **373-384**
described, 373
detection of, 376-380
mechanisms of, 374-376
prognosis of, 380
- Renal replacement therapy
blood pressure effects of, 386-387
calcium-phosphate metabolism effects of, 387-388
cardiovascular disease in patients on, 349-350
cardiovascular events due to, 388-389
effects on cardiac geometry, 387
effects on systolic function, 387
future directions in, 389

- homocysteine levels and, 388
hyperparathyroidism effects of, 387–388
lipid profile effects of, 387
newer paradigms in, **385–391**
nocturnal hypoxemia and, 388
- Renal transplant recipients, cardiovascular disease in
causes of, 331–335
CHF and, 333–334
incidence of, 332
ischemic heart disease and, 334–335
left ventricular hypertrophy and, 332–333
management of, **331–342**
anemia management in, 338
antiplatelet agents in, 337
beta-blockers in, 337
blood pressure targets in, 336
cholesterol reduction in, 335–336
lifestyle modification in, 335
renin-angiotensin antagonists in, 336–337
revascularization in, 338–339
risk-factor modification in, 335–338
prevalence of, 332
risk factors for, 332–335
nontraditional, 338
- Renin-angiotensin antagonists, in cardiovascular disease in renal transplant recipients management, 336–337
- Renin-angiotensin system
in diabetes mellitus, **167–185**. See also *Diabetes mellitus, renin-angiotensin system in*.
in hypertension, 238
interruption of, in CHF in CKD management, 279
- Reperfusion therapy, for ACSs, 407
- Revascularization interventions, in prevention of cardiovascular outcomes in type 2 diabetes, 218
- S**
- Scintigraphy, myocardial, *vs.* exercise testing, in CPUs, 511–512
- Second National Health and Nutrition Examination Survey mortality study, 346
- Secretagogue(s)
insulin, 123–126. See also *Insulin secretagogues*.
nonsulfonylurea, 127
limitations of, 127
mechanism of action of, 127
- Selectin(s), as biomarker of inflammation, 495
- Sensitivity, in suspected ACS evaluation, 518–519
- Septum, atrial, anatomy of, 36–37
- Serum amyloid A, as biomarker of inflammation, 495
- Shunt(s), intracardiac, closure of, effect on migraines, 94
- Smoking cessation
for CHF in CKD, 279
for peripheral arterial disease in CKD, 229–230
- Sodium, in hypertension, 237–238
- Spasm, coronary, NOCAD due to, 561, 563–564
- ST elevation, in ED and CPU patients, troponin for, 456–457
- STARFlex septal occluder, in patent foramen ovale closure, 78
- Statin(s)
for CHF in CKD, 279
for cholesterol reduction, in cardiovascular disease in renal transplant recipients management, 335–336
for peripheral arterial disease in CKD, 228–229
- ST-elevation myocardial infarction (STEMI), recognition and treatment of, thrombolytic predictive instrument in, 606
- STEMI. See *ST-elevation myocardial infarction (STEMI)*.
- Stent(s), coated, for venous neointimal hyperplasia in dialysis access, 265
- Stress, oxidative. See *Oxidative stress*.
- Stroke
described, 7
patent foramen ovale and, 7–11
- Sulfonylurea(s), 123–126
described, 123–124
mechanism of action of, 124–126
- Sympathetic nervous system, in hypertension, 239–240
- T**
- Technetium-99m sestamibi myocardial perfusion imaging, missed diagnoses of ACS in ED due to, 440

- Therapeutic turnaround time (TTAT), in cardiac biomarker POCT, 477-478
- Thiazide diuretics, for diabetes and hypertension, 143-144
- Thiazolidinedione(s), in prevention of cardiovascular disease in diabetics, 128-131
blood pressure effects of, 129-130
described, 128
endothelial function effects of, 130-131
lipid metabolism and oxidation in, 129
mechanism of action of, 128-129
vascular reactivity effects of, 130-131
vascular wall abnormalities due to, 130-131
- Three-dimensional echocardiography
in patent foramen ovale closure device placement, 60-64
in patent foramen ovale diagnosis, 51
- Thrombolysis, for ACSs, 406-407
- Thrombolytic predictive instrument
clinical effectiveness trial, 606-608
in recognition and treatment of STEMI, 604
- Thrombosis, in diabetes mellitus, 203-204
- Time-insensitive predictive instrument (TIPI)
information system cardiac error reduction system, based on ACI-TIPI demonstration project, 608-611
- Timeliness, in cardiac biomarker POCT, 478-479
- TIPI. See *Time-insensitive predictive instrument (TIPI)*.
- Toxin(s), in hypertension, 240
- Tracer injection, in suspected ACS evaluation, timing of, 523-524
- Transcatheter patch occlusion, in patent foramen ovale closure, 80-81
- Transesophageal echocardiography
in patent foramen ovale closure device placement, 54-57
in patent foramen ovale diagnosis, 49-50
- Trans-theoretic Y model application, of CPUs, 594, 596-598
- Transthoracic echocardiography, in patent foramen ovale diagnosis, 47-49
- Troponin
in ED and CPUs, 453-455
for high-risk patients with ACSs, 457-458
for intermediate and low risk patients, 458-460
for patients with ST elevation and myocardial infarction, 456-457
for renal failure patients, 460-461
in suspected ACS evaluation, 523
missed diagnoses of ACS in ED due to, 438
- Troponin I, myocardial stress and, 357-358
- Troponin T, myocardial stress and, 357-358
- TTAT. See *Therapeutic turnaround time (TTAT)*.
-
- U**
- Unbound free fatty acid, as biomarker of cardiac ischemia, 496
- Uremia
antioxidants in, 324-325
arteriosclerotic cardiovascular disease and, 354
oxidative stress and inflammation in, myeloperoxidase and, 323-324
-
- V**
- VADT trial, in prevention of cardiovascular outcomes in type 2 diabetes, 215
- Valve replacement, in CKD, 350
- Valvular disease, microvascular dysfunction and, NOCAD due to, 562
- Vascular calcification
CKD and, 357
in renal failure, 373-384. See also *Renal failure, vascular calcification in*.
- Vascular endothelial function, renin angiotensin system in, in diabetes mellitus, 172-173
- Vasodilator(s), in ADHF management in EDOU, 582
- Venous neointimal hyperplasia, in dialysis access, novel therapies for, 264-266
- Vitamin E-bonded hemodialyzers, 326
-
- W**
- Water, in hypertension, 237-238
- Weight, body, cardiovascular disease in diabetics and, 132
- Whole blood choline, as biomarker of plaque instability or rupture, 497
- Women, in CPUs, management of, 549-551

